DXCM vs EW
Dexcom and Edwards Lifesciences, both Healthcare
Edwards Lifesciences is the larger company at $50B against $28B. On trailing earnings DXCM is the cheaper of the two at a P/E of 33.4 against 49.0, a gap that is only a bargain if the two are growing at similar rates. Over the past year EW returned +14% against +11% for DXCM. The RyuScore puts DXCM ahead, 73 against 60 out of 100.
| Figure | DXCM | EW |
|---|---|---|
| Last close | $84.10 | $85.20 |
| Market cap | $28B | $50B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 33.4 | 49.0 |
| 1-year return | +11% | +14% |
| 5-year return | -38% | -29% |
| RyuScoresector-relative, 1–10 | 73/100 | 60/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Dexcom
Revenue of $1.3B in Q2 2026, net income $249M. Its largest reported line is United States, 81% of the disclosed total.
Edwards Lifesciences
Revenue of $1.7B in Q2 2026, net income $241M. Its largest reported line is Transcatheter Aortic Valve Replacement, 72% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.